The cost‐effectiveness of testing for NS5a resistance‐associated polymorphisms at baseline in genotype 1a‐infected (treatment‐naïve and treatment‐experienced) subjects treated with all‐oral elbasvir/grazoprevir regimens in the United States

BACKGROUND: The presence of baseline NS5A resistance‐associated variants (RAVs) impacted treatment response in HCV genotype 1a (GT1a)‐infected patients treated with elbasvir/grazoprevir (EBR/GZR) for 12 weeks, but not patients treated with EBR/GZR and ribavirin (RBV) for 16 weeks. AIMS: To assess th...

Descripción completa

Detalles Bibliográficos
Autores principales: Elbasha, E. H., Robertson, M. N., Nwankwo, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Elbasvir plus Grazoprevir for HCV
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680317/
https://www.ncbi.nlm.nih.gov/pubmed/27910116
http://dx.doi.org/10.1111/apt.13882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680317/
https://www.ncbi.nlm.nih.gov/pubmed/27910116
http://dx.doi.org/10.1111/apt.13882

Ejemplares similares